Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)

NCT05046795 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

258

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD

Interventions

DRUG: Revefenacin 175 mcg in 3 ML Inhalation Solution
DRUG: Placebo inhalation solution QD

Sponsor

Mylan Pharma UK Ltd.